CD274 and metastatic melanoma: Therefore, the objective of this SLR was to understand the real-world OS of patients with advanced/metastatic melanoma, NSCLC, or RCC who would currently be eligible, based on their clinical presentation, for treatment with an anti-PD-(L)1 agent but were treated with conventional care before the regulatory approval of anti-PD-(L)1 therapy and of patients treated with anti-PD-(L)1 agents after their approval.